Rinnerthaler, G., Gampenrieder, S. P., Hackl, H., Steiner, M., Monzo-Fuentes, C., Melchardt, T., . . . Greil, R. (2020). Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. J Clin Med.
Stile di citazione ChicagoRinnerthaler, Gabriel, et al. "Low Expression of MiR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated Within the TANIA Phase III Trial." J Clin Med 2020.
Citazione MLARinnerthaler, Gabriel, et al. "Low Expression of MiR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated Within the TANIA Phase III Trial." J Clin Med 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.